Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
Existing therapies for vitiligo are limited in efficacy and can be associated with undesirable side effects. Topical Janus kinase inhibitors may offer a new therapeutic option for vitiligo.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου